First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027 Cash equivalents of 53.3 million as of September 30, 2026 pro forma cash balance of approximately 72.0 million after
Why Is Equillium, Inc. (EQ) Stock Up Today?
Updated Nov 19, 2026 7:00 PM ET · Prev Close $1.10
Primary Move Catalyst & Conviction
65% Signal ConvictionPharmaceuticals & Therapeutics sector moving together
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 1.4% on average.
Market & Sector Relative Strength
EQ outperforming the S&P 500 by +3.78%Options Flow & Execution Desk
Bullish Flow · P/C 0.02Unlock 1 Unusual EQ Options Sweep Strike
See exact institutional strike concentrations, volume-to-OI ratios, and multi-leg payoff blueprints with Tradestie Pro.
Recent EQ Catalyst Headlines
Verified WireTopline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of 20 million in additio
New preclinical data further characterizes EQ504 s coordinated effects across epithelial and immune compartments in intestinal inflammationLA Jolla, Calif., Oct. 06, 2026 Globe Newswire -- Equillium, Inc. Nasdaq EQ , a b
On track to initiate dosing by early November 2026 topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation Randomized, double-blind, placebo-controlled study will evaluate
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for breakdown below $1.05
Technical Regime (EQ)
BEARISH MA TREND1-Year Historical Move Analogs
74 EventsSessions in the past year where EQ moved >3.0% down:
Retail & Crowd Sentiment
BullishUser @Bennyst expresses bullish sentiment towards $EQ on StockTwits, predicting similar performance.
About Equillium, Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through pa...
Get Instant EQ Catalyst Alerts
Receive an email alert when EQ triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversEQ Session & Catalyst FAQ
Why is EQ stock up today?
This appears to be a sector-wide move. The Pharmaceuticals & Therapeutics sector is down 1.4% on average.
Is EQ stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 0.96x relative volume (low participation). Our multi-factor model currently rates EQ as HOLD. Review full valuation, quality, and timing signals on the EQ Buy or Sell Decision Brief →
What is EQ's intrinsic value and expected trading range?
At $1.12, EQ's modeled 1-to-3 session range is $1.02 – $1.08, with a key inflection level at $1.00 (support). Compare current price against multi-year cash flow projections in the EQ Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for EQ?
RSI at 36.0 reflects soft below-midline momentum. EQ trades at $1.12 relative to its 20-day SMA ($1.33) and 50-day SMA ($1.49), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.